Literature DB >> 10564593

Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines.

T Knutsen1, V K Rao, T Ried, L Mickley, E Schneider, K Miyake, B M Ghadimi, H Padilla-Nash, S Pack, L Greenberger, K Cowan, M Dean, T Fojo, S Bates.   

Abstract

Molecular cytogenetic studies were conducted on three multidrug-resistant cancer sublines which are highly resistant to the chemotherapeutic agent mitoxantrone, an anthracenedione. The three independently selected sublines were derived by exposure to mitoxantrone or Adriamycin and do not overexpress MDR1 or MRP. Two sublines, MCF-7 AdVp3000 and MCF-7 MX, showed an amplification peak at 4q21-q22, as demonstrated by comparative genomic hybridization (CGH), while the third, S1-M1-80, did not. FISH using a whole chromosome 4 paint demonstrated multiple rearrangements involving chromosome 4 in MCF-7 AdVp3000 and MCF-7 MX, while S1-M1-80 contained only a simple reciprocal translocation. The parental cell lines had no chromosome 4 rearrangements and no copy number gain or amplification of chromosome 4. Spectral karyotyping (SKY) analysis revealed a balanced translocation, t(4;17)(q21-q22;p13) in S1-M1-80 and multiple clonal translocations involving chromosome 4 in MCF-7 AdVp3000 and MCF-7 MX. A novel cDNA, designated MXR, which encodes an ABC half-transporter and is highly overexpressed in the three sublines, was localized to chromosome 4 by somatic cell hybrid analysis. Southern blot analysis demonstrated amplification of the MXR gene in MCF-7 AdVp3000 and MCF-7 MX, but not in S1-M1-80. FISH studies with a BAC probe for MXR localized the gene to 4q21-22 in the normal chromosome 4 and revealed in both MCF-7 AdVp3000 and MCF-7 MX amplification of MXR at one translocation juncture, shown by SKY to be t(4;5)(4qter-->4cen-->4q21-22::5q13-->5qter++ +) in MCF-7 AdVp3000 and t(6;4;6;3)(6pter-->6q15::4q21-q22::hsr::6q?::3q?27-->+ ++3qter) in MCF MX; neither of the breakpoints in the partner chromosomes showed amplification by CGH. The data are consistent with the hypothesis of a transporter, presumably that encoded by the MXR gene, mediating mitoxantrone resistance. The MXR gene encodes a half-transporter and the absence of cytogenetic evidence of coamplification of other regions suggests that a partner may not be overexpressed, and instead the MXR half-transporter homodimerizes to mediate drug transport. Genes Chromosomes Cancer 27:110-116, 2000. Published 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10564593

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  24 in total

Review 1.  The role of half-transporters in multidrug resistance.

Authors:  S E Bates; R Robey; K Miyake; K Rao; D D Ross; T Litman
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

Review 2.  ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.

Authors:  Maryam Hosseini Hasanabady; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

3.  ABCG2 expression, function, and promoter methylation in human multiple myeloma.

Authors:  Joel G Turner; Jana L Gump; Chunchun Zhang; James M Cook; Douglas Marchion; Lori Hazlehurst; Pamela Munster; Michael J Schell; William S Dalton; Daniel M Sullivan
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

4.  Human ABCG2: structure, function, and its role in multidrug resistance.

Authors:  Wei Mo; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2011-03-30

5.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

Authors:  Eran E Bram; Michal Stark; Shachar Raz; Yehuda G Assaraf
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.

Authors:  Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Methods Mol Biol       Date:  2010

7.  MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells.

Authors:  Yu-Zhuo Pan; Marilyn E Morris; Ai-Ming Yu
Journal:  Mol Pharmacol       Date:  2009-03-06       Impact factor: 4.436

8.  Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line.

Authors:  Kenneth K W To; Zhirong Zhan; Thomas Litman; Susan E Bates
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

9.  Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.

Authors:  Kenneth K W To; Orsolya Polgar; Lyn M Huff; Kuniaki Morisaki; Susan E Bates
Journal:  Mol Cancer Res       Date:  2008-01       Impact factor: 5.852

Review 10.  ABCG2: a perspective.

Authors:  Robert W Robey; Kenneth K K To; Orsolya Polgar; Marius Dohse; Patricia Fetsch; Michael Dean; Susan E Bates
Journal:  Adv Drug Deliv Rev       Date:  2008-12-16       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.